Log in

Relevant bibliographies by topics / Lupus erythematosus / Journal articles

To see the other types of publications on this topic, follow the link: Lupus erythematosus.

Journal articles on the topic 'Lupus erythematosus'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lupus erythematosus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Chinnusamy, Manokaran, Ram Arvind Viswanathan, Sathiyanarayanan Janakiraman, and Roshna Elayidath. "Drug-Induced Lupus Erythematosus Associated with Proton Pump Inhibitor." Journal of Health and Allied Sciences NU 10, no. 03 (September 8, 2020): 132–34. http://dx.doi.org/10.1055/s-0040-1716601.

Full text

Abstract:

AbstractDrug-induced lupus erythematosus is an autoimmune phenomenon where the drug exposure leads to the development of systemic lupus erythematous like clinical features. Drug-induced lupus erythematosus can be divided into systemic lupus erythematous, subacute cutaneous lupus erythematous, and chronic cutaneous lupus erythematous. Here, we report a case of a 29-year-old female presented with systemic lupus erythematous due to chronic use of proton pump inhibitors, which is considered to be very rare.

APA, Harvard, Vancouver, ISO, and other styles

2

Garbelini-Lima, Cleide, Gabriela Evangelista de Almeida, Sidharta Quércia Gabdelha, Andrea Cavalcante de Souza, Mara Lúcia Gomes de Souza, and Virginia Vilasboas Figueiras. "Discoid Lupus Erythematosus of the Scalp in a Patient with Systemic Lupus Erythematosus: A Case Report with Complete Hair Regrowth." Journal of the Portuguese Society of Dermatology and Venereology 79, no. 2 (June 26, 2021): 155–58. http://dx.doi.org/10.29021/spdv.79.2.1283.

Full text

Abstract:

Scalp involvement with hair loss is common in systemic lupus erythematosus. Discoid lupus erythematosus may cause scarring alopecia, characterized by well-delimited erythematous plaques with scales, follicular hyperkeratosis and atrophy, which is considered a trichological emergency. Early diagnosis and treatment are necessary in order to prevent permanent hair loss. We describe a 44 years’ old female patient with systemic lupus erythematosus for 4 years, with multiple areas of occipitoparietal alopecia, erythematous plaques, atrophy, scales and some bloody crusts. Trichoscopy, histopathology and direct immunofluorescence led to the diagnosis of discoid lupus erythematosus. After 9 months treatment with thalidomide there was complete hair regrowth.

APA, Harvard, Vancouver, ISO, and other styles

3

Frey, Marcos Noronha, Ana Elisa Empinotti Ioppi, Gabriela Czarnobay Garbin, Roque Domingos Furian, and Ana Elisa Kiszewski Bau. "Congenital and neonatal lupus erythematosus: two case reports." Anais Brasileiros de Dermatologia 87, no. 4 (August 2012): 625–28. http://dx.doi.org/10.1590/s0365-05962012000400019.

Full text

Abstract:

Neonatal lupus erythematosus is an autoimmune disease produced by the passage of maternal antinuclear antibodies and extractable nuclear antigen antibodies through the placenta. At the moment of the diagnosis, the mothers are asymptomatic in 40 to 60% of cases. The most common manifestations are cutaneous lesions and congenital heart block. The cutaneous findings are variable and usually begin within the first weeks or months of life. Congenital lupus erythematosus is a congenital variant of neonatal lupus erythematosus. We present one case of congenital lupus erythematosus and one case of neonatal lupus erythematous, showing the variability of this disease.

APA, Harvard, Vancouver, ISO, and other styles

4

Huzairi Sani, Nada Syazana, and Malek Faris Riza Feisal. "A different kind of skin presentation in Systemic Lupus Erythematosus (SLE): A case report." Asian Journal of Medicine and Biomedicine 4, no. 1 (April 24, 2020): 42–46. http://dx.doi.org/10.37231/ajmb.2020.4.1.329.

Full text

Abstract:

Erythema nodosum is a septal panniculitis which is a variant of chronic cutaneous lupus erythematosus (CCLE). It is further classified in the group of Lupus Erythematous Panniculitis (LEP).[1] The most frequent cutaneous manifestations include indurated plaques, subcutaneous nodules and sometimes ulcerations. The lesions occur predominantly on the face, upper arms, upper trunk, breasts, buttocks and thighs.[2] They occur most frequently in adult females and do not typically manifest cutaneously in Systemic Lupus Erythematosus (SLE).[3] In this case report, we discuss a young gentleman who presented with erythema nodosum as a cutaneous feature of SLE. Keywords: Systemic lupus erythematosus, erythema nodosum, panniculitis, cutaneous lupus

APA, Harvard, Vancouver, ISO, and other styles

5

Guleva, D., M. Balabanova, L. Miteva, and L. Dourmishev. "Histology of Skin Alterations in Lupus Erythematosus." Acta Medica Bulgarica 49, no. 2 (June 1, 2022): 28–32. http://dx.doi.org/10.2478/amb-2022-0016.

Full text

Abstract:

Abstract Lupus erythematosus is an autoimmune connective tissue disorder showing a broad spectrum of clinical manifestations. The aim of this study was to assess the correlation of skin histology and different types of lupus erythematosus. Materials and methods: Fifty-one skin specimens were assessed from 39 female and 12 male patients with acute, subcutaneous and chronic lupus erythematosus, diagnosed and treated in the Department of Dermatology and Venereology, Alexandrovska University Hospital for a 4-year period. Results: Follicular hyperkeratosis, epidermal atrophy, vacuolar degeneration and interface dermatitis were the most frequently observed lesions in chronic cutaneous lupus erythematosus while diffuse hyperkeratosis, epidermal atrophy and indistinct interface dermatitis in the dermis were predominant in subacute cutaneous lupus erythematosus. Lupus tumidus, a rare intermittent variant of cutaneous lupus erythematosus, showed almost no epidermal involvement and mucin deposition in the dermis. However, in one of our lupus tumidus patients the disease progressed to a systemic form with histological changes of acute cutaneous lupus erythematosus including atrophy, dermal-epidermal smoothing and lymphocytic infiltration in the dermis. Of note, a few patients showed histological changes of urticarial vasculitis-like and rheumatic-like patterns. Conclusion: The correlation of clinical course, histopathological findings and immunological tests are of vital importance for the correct diagnosis and follow up of patients with lupus erythematodes, thus preventing complications and improving their quality of life.

APA, Harvard, Vancouver, ISO, and other styles

6

Mrabat, Samia, Hanane aybay, Zakia Douhi, Sara Elloudi, Fatima Zahra Mernissi, and Mouna Rimani. "Cutaneous lupus tumidus: An unusual unilateral presentation." Our Dermatology Online 12, no. 2 (April 1, 2021): 151–52. http://dx.doi.org/10.7241/ourd.20212.10.

Full text

Abstract:

Lupus tumidus is a rare subtype of chronic cutaneous lupus erythematosus characterized by erythema and bright urticarial erythematous and violaceous lesions on sun-exposed areas that heal without leaving scars. Lupus tumidus follows a benign and intermittent clinical course and is rarely associated with systemic lupus erythematosus. Treatment involves photoprotection, topical corticosteroids, and antimalarials. We report the case of a 42-year-old patient with an atypical unilateral form of lupus tumidus successfully treated with the administration of hydroxychloroquine in combination with photoprotection and tacrolimus.

APA, Harvard, Vancouver, ISO, and other styles

7

Kim, Esther K., Peter W. Hashim, and Saakshi Khattri. "Subacute Cutaneous Lupus Erythematosus Coexisting in a Patient with Plaque Psoriasis." Journal of Psoriasis and Psoriatic Arthritis 2, no. 2 (March 2017): 62–64. http://dx.doi.org/10.1177/247553031700200204.

Full text

Abstract:

Subacute cutaneous lupus erythematosus (SCLE) is a form of cutaneous lupus erythematosus that is characterized by nonscarring, erythematous, annular eruptions occurring mainly on sun-exposed areas. The incomplete understanding of SCLE creates challenges in diagnosis and treatment. This report describes the rare case of SCLE co-existing with plaque psoriasis.

APA, Harvard, Vancouver, ISO, and other styles

8

Paul, Sujat. "Lupus With Pregnancy : Beyond the Basics." Journal of Chittagong Medical College Teachers' Association 23, no. 1 (September 22, 2012): 53–56. http://dx.doi.org/10.3329/jcmcta.v23i1.51898.

Full text

Abstract:

Pregnancy in patients with systemic lupus erythematosus is associated with a high risk of maternal disease exacerbation and adverse fetal outcome. This review summarizes recent published findings on lupus pregnancy. Literature review: The literature has profound agreement on thefact that, for most women with inactive and stable systemic lups erythematousus, pregnancy is safe for both mother and fetus. The main risk factors for adverse pregnancy course and outcome are active disease, nephritis with proteinuria, hypertension and maternal serum antibodies to SS-A/Ro, SS-B/La, cardiolipin, 2-glycoprotein I, and lupus anticoagulant. Recent studies have broadened our understanding of the immunological mechanism underlying congenital heart block induced by anti-Ro/La antibodies. Pregnancy in patients with systemic lupus erythematosus is safe and manageable provided the disease is stable. Patients should be closely followed up before pregnancy for pregestational risk factors and should get extra attention during gregnancy. The disease can be safely managed in some cases of lupus flare during pregnancy. JCMCTA 2012; 23(1): 53-56

APA, Harvard, Vancouver, ISO, and other styles

9

N, Habib. "Review Article: Systemic Lupus Erythematosus." Open Access Journal of Microbiology & Biotechnology 5, no. 1 (2020): 1–4. http://dx.doi.org/10.23880/oajmb-16000158.

Full text

Abstract:

Systemic lupus erythematosus or SLE is a persistent heterogeneous autoimmune disease that affects multisystem of the body. It is distinguished by acute and chronic inflammation of various tissues and even organs of the body principally the skin and joints. Systemic lupus erythematosus is a multisystem disorder and hence, it can affect any tissues, organs and even systems of the body. There are few categories of lupus for instance, lupus dermatitis or cutaneous lupus erythematosus (CLE) that affects the skin and causes malar rash, discoid lupus erythematosus (DLE) as well as systemic lupus erythematosus that causes damage to single or multiple internal organs. The damage is due to the inflammation that is caused by direct antibody reaction to the body tissues as well the deposition of immune complexes. Glucocorticoids, immunosuppressant, and anti- malarial are the combination therapy used to treat SLE besides providing counseling and awareness. Lupus erythematosus in any form particularly systemic lupus erythematosus (SLE) are prevalent in women compared to men with ratio of 6:1. It has the tendency to affect all ages but most frequently attacks women of aged 20 to 45 years old compared to men. On the other hand, if lupus erythematosus causes damage to internal organs either single or multiple, it is known as systemic lupus erythematosus. The damage is due to the inflammation that is caused by direct antibody reaction to the body tissues as well the deposition of immune complexes.

APA, Harvard, Vancouver, ISO, and other styles

10

Franjic, Sinisa. "Systemic Lupus Erythematosus in Gynecology." International Journal of Reproductive Research 1, no. 1 (December 22, 2022): 01–03. http://dx.doi.org/10.58489/2836-2225/005.

Full text

Abstract:

Systemic lupus erythematosus is a chronic autoimmune disease that can affect various organs and parts of the body, especially the skin, joints, blood, kidneys, and central nervous system. Systemic lupus erythematosus is not a contagious disease, it is an autoimmune disease in which the immune system loses the ability to distinguish foreign from the patient's own tissues and cells. The immune system makes mistakes and produces, among other things, autoantibodies that recognize their own cells as foreign and attack them. The result is an autoimmune reaction that causes inflammation. Inflammation means that the affected part of the body becomes warm, red, swollen and sometimes painfully sensitive. If the signs of inflammation are long-lasting, as they may be in the case of systemic lupus erythematosus, tissue damage and its normal function may occur. Therefore, the goal of treatment of systemic lupus erythematosus is to alleviate inflammation. A number of hereditary risk factors along with various environmental factors are thought to be responsible for this impaired immune response. Systemic lupus erythematosus is known to be caused by a variety of factors, including hormonal imbalances during puberty, stress, and environmental factors such as sun exposure, viral infections, and medications.

APA, Harvard, Vancouver, ISO, and other styles

11

Powers, David B. "Systemic Lupus Erythematosus and Discoid Lupus Erythematosus." Oral and Maxillofacial Surgery Clinics of North America 20, no. 4 (November 2008): 651–62. http://dx.doi.org/10.1016/j.coms.2008.07.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Shenoy, Manjunath M., Goutham Kilaru, Ashmiya Razak, and Malcolm Pinto. "Atypical dermatophytosis in a case of systemic lupus erythematosus." Our Dermatology Online 11, e (December 17, 2020): e165.1-e165.3. http://dx.doi.org/10.7241/ourd.2020e.165.

Full text

Abstract:

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune connective tissue disease with many muco-cutaneous manifestations. We report a case of SLE on treatment presented with scaly erythematous plaques on the trunk and extremities and diffuse scaly erythematous macular lesions on the face resembling cutaneous lupus erythematosus. Laboratory evaluation established a diagnosis of tinea corporis with faciei. He responded to long term itraconazole therapy. This case focuses on the modification of tinea in an autoimmune disorder on immunosuppressive therapy and its therapeutic implications.

APA, Harvard, Vancouver, ISO, and other styles

13

Stead, Jennifer, Catherine Headley, Michael Ioffreda, Carrie Kovarik, and Victoria Werth. "Coexistence of Tumid Lupus Erythematosus With Systemic Lupus Erythematosus and Discoid Lupus Erythematosus." JCR: Journal of Clinical Rheumatology 14, no. 6 (December 2008): 338–41. http://dx.doi.org/10.1097/rhu.0b013e31817d1183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Le, Marilyn, Payvand Kamrani, and L. Claire Hollins. "Coexistentence of Morphea and DLE in a Patient with Beta Thalassemia Leading to a Diagnosis of Systemic Lupus Erythematous." SKIN The Journal of Cutaneous Medicine 6, no. 3 (May 6, 2022): 243–45. http://dx.doi.org/10.25251/skin.6.3.11.

Full text

Abstract:

Patients with autoimmune disorders are predisposed to developing a second autoimmune condition. This can be applied to cutaneous conditions as well. Morphea or localized scleroderma is an autoimmune inflammatory and fibrosing skin disorder due to increased collagen deposition.1,2 Patients with morphea are four times likelier of having a concomitant autoimmune disease.1 There have been cases of systemic lupus erythematosus (SLE) with morphea, but the co-occurrence of discoid lupus erythematosus (DLE) with morphea has been rarely reported, and never reported in patient with Beta-thalamessmia.1,2,7 Morphea and discoid lupus erythematosus can be found within one lesion or as separate diagnoses. In this case, we describe a patient with morphea and discoid lupus erythematous in the setting of beta thalassemia leading to diagnosis of SLE.

APA, Harvard, Vancouver, ISO, and other styles

15

Cooper, Elizabeth E., Catherine E. Pisano, and Samantha C. Shapiro. "Cutaneous Manifestations of “Lupus”: Systemic Lupus Erythematosus and Beyond." International Journal of Rheumatology 2021 (May 18, 2021): 1–19. http://dx.doi.org/10.1155/2021/6610509.

Full text

Abstract:

Lupus, Latin for “wolf,” is a term used to describe many dermatologic conditions, some of which are related to underlying systemic lupus erythematosus, while others are distinct disease processes. Cutaneous lupus erythematosus includes a wide array of visible skin manifestations and can progress to systemic lupus erythematosus in some cases. Cutaneous lupus can be subdivided into three main categories: acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus. Physical exam, laboratory studies, and histopathology enable differentiation of cutaneous lupus subtypes. This differentiation is paramount as the subtype of cutaneous lupus informs upon treatment, disease monitoring, and prognostication. This review outlines the different cutaneous manifestations of lupus erythematosus and provides an update on both topical and systemic treatment options for these patients. Other conditions that utilize the term “lupus” but are not cutaneous lupus erythematosus are also discussed.

APA, Harvard, Vancouver, ISO, and other styles

16

Ramírez-Marín, Hassiel Aurelio, Ahmad Aleisa, Anabell Andrea Lima-Galindo, and Silvia Mendez-Flores. "Cutaneous lupus: Immunofluorescence and lupus band test." Our Dermatology Online 13, no. 2 (April 1, 2022): 202–9. http://dx.doi.org/10.7241/ourd.20222.21.

Full text

Abstract:

Cutaneous lupus erythematosus is an autoimmune disease with a broad range of clinical findings. There are several methods to conduct a diagnostic approach, among these stands direct immunofluorescence, in which we can find the Lupus Band Test (LBT) consisting of a band of granular deposits of immunoglobulins and complement along the dermo-epidermal junction. It can have a high sensitivity and specificity for diagnosis in some cases, according to the biopsy site, the constituents of immunorreactants found at the dermoepidermal junction, and the morphology and intensity of the immunofluorescent band. Certain limitations of the test should be considered when interpreting the results. Although useful in diagnosis, the lupus band is not considered a pathognomonic sign of erythematous lupus. About one-third of patients with positive direct immunofluorescence on a skin biopsy do not have systemic lupus erythematosus (SLE). A positive LBT in non-lesional photoprotected skin represents a criterion with high specificity to identify patients with SLE.

APA, Harvard, Vancouver, ISO, and other styles

17

Richter, JG, O. Sander, M. Schneider, and P. Klein-Weigel. "Diagnostic algorithm for Raynaud’s phenomenon and vascular skin lesions in systemic lupus erythematosus." Lupus 19, no. 9 (August 2010): 1087–95. http://dx.doi.org/10.1177/0961203310374304.

Full text

Abstract:

Skin discolorations and skin lesions due to vascular pathologies are common clinical features in systemic lupus erythematosus. A variety of clinical manifestations such as Raynaud’s phenomenon, acrocyanosis, livedo patterns, erythematous or violaceous macules and papules or necrosis are triggered by heterogeneous pathophysiological mechanisms such as vasospasm, vasculitis or thromboembolism. A standardized macro- and microvascular assessment is necessary to establish the correct diagnosis. We describe and illustrate common clinical features of vascular skin manifestations in systemic lupus erythematosus and present a diagnostic algorithm. Lupus (2010) 19, 1087—1095.

APA, Harvard, Vancouver, ISO, and other styles

18

Hymes, Sharon R., Robert E. Jordon, and Frank C. Arnett. "Lupus Erythematosus." Dermatologic Clinics 4, no. 2 (April 1986): 267–76. http://dx.doi.org/10.1016/s0733-8635(18)30831-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Passarini, B., E. Spettoli, G. Borda, and J. Lehinann. "LUPUS ERYTHEMATOSUS." American Journal of Dermatopathology 16, no. 1 (February 1994): 109. http://dx.doi.org/10.1097/00000372-199402000-00090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Chottawornsak, N., P. Rodsaward, S. Suwannachote, M. Rachayon, T. Rattananupong, T. Deekajorndech, P. Asawanonda, D. Chiewchengchol, and P. Rerknimitr. "Skin signs in juvenile- and adult-onset systemic lupus erythematosus: clues to different systemic involvement." Lupus 27, no. 13 (October 18, 2018): 2069–75. http://dx.doi.org/10.1177/0961203318805851.

Full text

Abstract:

Objective We aim to explore the differences of skin signs between juvenile- and adult-onset systemic lupus erythematosus and to identify their associations to the development of systemic involvement. Methods A retrospective chart review of 377 systemic lupus erythematosus patients was performed. Results In total, 171 patients with juvenile systemic lupus erythematosus and 206 with adult systemic lupus erythematosus were studied. All patients were of Southeast Asian descent. The mean duration of follow up was 8.18 ± 6.19 and 9.36 ± 7.68 years for juvenile systemic lupus erythematosus and adult systemic lupus erythematosus, respectively. At diagnosis, most patients presented with acute cutaneous lupus erythematosus, whereas chronic cutaneous lupus erythematosus was twice as common in adult systemic lupus erythematosus ( p < 0.001). The mean Systemic Lupus Erythematosus Disease Activity Index of juvenile systemic lupus erythematosus was significantly higher than that of adult systemic lupus erythematosus (14.29 ± 7.13 vs 11.27 ± 6.53). Multivariate analysis revealed the following associations in juvenile systemic lupus erythematosus: acute cutaneous lupus erythematosus and non-scarring alopecia with increased risk of arthralgia, mucosal ulcers with leukopenia, cutaneous vasculitis with seizure, and finding of granular casts. On the contrary, the associations for adult systemic lupus erythematosus were oral ulcers with arthralgia and cutaneous vasculitis with myositis. Conclusions Cutaneous signs in systemic lupus erythematosus may signal prognostic implication. Interestingly, despite similar cutaneous lesions in systemic lupus erythematosus, different ages of onset are associated with different systemic involvement.

APA, Harvard, Vancouver, ISO, and other styles

21

NITTA, Y. "Lupus erythematosus profundus associated with neonatal lupus erythematosus." British Journal of Dermatology 136, no. 1 (January 1997): 112–14. http://dx.doi.org/10.1046/j.1365-2133.1997.d01-1154.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

NITTA, Y. "Lupus erythematosus profundus associated with neonatal lupus erythematosus." British Journal of Dermatology 136, no. 1 (January 1997): 112–14. http://dx.doi.org/10.1111/j.1365-2133.1997.tb08758.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Callen, Jeffrey P. "Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus." Journal of the American Academy of Dermatology 40, no. 1 (January 1999): 129. http://dx.doi.org/10.1016/s0190-9622(99)70548-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Obermoser, G., RD Sontheimer, and B. Zelger. "Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates." Lupus 19, no. 9 (August 2010): 1050–70. http://dx.doi.org/10.1177/0961203310370048.

Full text

Abstract:

The skin is the second most frequently affected organ system in lupus erythematosus. Although only very rarely life threatening — an example is lupus erythematosus-associated toxic epidermal necrolysis — skin disease contributes disproportionally to disease burden in terms of personal and psychosocial wellbeing, vocational disability, and hence in medical and social costs. Since several manifestations are closely associated with the presence and activity of systemic lupus erythematosus, prompt and accurate diagnosis of cutaneous lupus erythematosus is essential. This review aims to cover common, rare, and atypical manifestations of lupus erythematosus-associated skin disease with a detailed discussion of histopathological correlates. Cutaneous lupus erythematosus covers a wide morphological spectrum well beyond acute, subacute and chronic cutaneous lupus erythematosus, which are commonly classified as lupus-specific skin disease. Other uncommon or less well-known manifestations include lupus erythematosus tumidus, lupus profundus, chilblain lupus, mucosal lupus erythematosus, and bullous lupus erythematosus. Vascular manifestations include leukocytoclastic and urticarial vasculitis, livedoid vasculopathy and livedo reticularis/ racemosa. Finally, we discuss rare presentations such as lupus erythematosus-related erythema exsudativum multiforme (Rowell syndrome), Kikuchi-Fujimoto disease, extravascular necrotizing palisaded granulomatous dermatitis (Winkelmann granuloma), and neutrophilic urticarial dermatosis. Lupus (2010) 19, 1050—1070.

APA, Harvard, Vancouver, ISO, and other styles

25

Sawallich, K., and P. von den Driesch. "Ein Fall von kutaner Lupus erythematodes-ähnlicher Tattoo-Reaktion (diskoider Lupus erythematodes bei rotem Tattoo): Histopathologie, Komplikationen und Therapie." Aktuelle Dermatologie 45, no. 08/09 (May 8, 2019): 398–401. http://dx.doi.org/10.1055/a-0864-4244.

Full text

Abstract:

ZusammenfassungDie kutane Lupus erythematodes-ähnliche Tattoo-Reaktion (diskoider Lupus erythematodes bei rotem Tattoo) ist die Diagnose einer seltenen, typischerweise histologisch gestellten Erkrankung, die bei Patienten im Rahmen von Tätowierungen mit rotem Farbstoff auftreten kann. Es kommt zu Schwellungen mit Induration, Juckreiz und Ausbildung von erhabenen, hyperkeratotischen Plaques im Bereich rot tätowierter Tattoos. Histologisch ist die kutane Lupus erythematodes-ähnliche Tattoo-Reaktion gekennzeichnet durch eine Interface-Dermatitis sowie eine lymphozytenreiche, perivaskuläre und periadnexielle Entzündung, die sehr an einen chronisch diskoiden Lupus erythematosus erinnert. Symptome eines systemischen Lupus erythematodes treten nicht auf. Therapeutisch sind läsionale oder orale Steroide empfohlen.

APA, Harvard, Vancouver, ISO, and other styles

26

Koch, K., and M. Tikly. "Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus." Lupus 28, no. 8 (June 19, 2019): 1021–26. http://dx.doi.org/10.1177/0961203319856091.

Full text

Abstract:

Background Cutaneous involvement is very common in systemic lupus erythematosus. We describe the prevalence and spectrum of lupus-specific (cutaneous lupus erythematosus) and non-specific cutaneous features amongst mostly black South Africans with systemic lupus erythematosus. Patients and methods A retrospective record review of 298 South Africans (262 blacks and 36 non-blacks) with systemic lupus erythematosus was carried out. Cutaneous features were classified according to the Gilliam and Sontheimer classification of cutaneous lupus. Results Most (81.5%) patients were black African females. The mean (SD) age at diagnosis and follow-up duration were 35.0 (11.8) and 8.0 (5.9) years, respectively. Cutaneous lupus erythematosus was seen in 76.1% of patients, mainly chronic cutaneous lupus erythematosus with the discoid lupus erythematosus subtype seen in 52.1% of patients. Acute cutaneous lupus erythematosus was seen in 30.2% of patients and was more common in non-blacks than blacks (odds ratio = 3.8 (1.9–7.9)); localized acute cutaneous lupus erythematosus was more common than generalized acute cutaneous lupus erythematosus (odds ratio = 2.6 (1.6–4.4)). Non-specific cutaneous features occurred in 77.2%, with oral/nasal ulcers and Raynaud’s phenomenon each occurring in approximately 40% of patients. Diffuse melanonychia at initial diagnosis was present in 37.4% of patients and was more common in blacks than non-blacks (odds ratio = 3.1 (1.3–7.3)). Acute cutaneous lupus erythematosus was associated with renal disease (odds ratio = 2.8 (1.6–4.7)) and chronic cutaneous lupus erythematosus with arthritis (odds ratio = 2.02 (1.24–3.29)). Diffuse melanonychia was associated with less renal disease and anti-dsDNA antibody positivity (odds ratio = 0.4 (0.3–0.7) and 0.4 (0.2–0.6), respectively) and significantly lower lupus severity index scores (mean (SD) = 5.99 (1.11) vs 6.56 (1.36) in patients with no melanonychia, p < 0.05)). Conclusion In this study of South Africans with systemic lupus erythematosus, the skin was the most commonly affected organ. In general, cutaneous lupus erythematosus was associated with less severe systemic disease. Acute cutaneous lupus erythematosus was less common in blacks, whereas discoid lupus erythematosus was more common than reported in Caucasians. Diffuse melanonychia was a distinctive finding and was associated with milder systemic disease.

APA, Harvard, Vancouver, ISO, and other styles

27

Karasińska, Aneta, Adriana Polańska, Monika Bowszyc‑Dmochowska, Ryszard Żaba, Zygmunt Adamski, and Aleksandra Dańczak‑Pazdrowska. "Discoid lupus erythematosus – a case report, diagnostic and therapeutic difficulties." Journal of Face Aesthetics 4, no. 2 (December 31, 2021): 135–44. http://dx.doi.org/10.20883/jofa.51.

Full text

Abstract:

Discoid lupus erythematosus is the most common clinical manifestation of lupus erythematosus. Characteristic features are erythematous plaques with follicular hiperkeratosis, clearly demarcated from surrounding skin, that resolve with atrophy and scarring, leading to significant aesthetic defects. The consequence of involving the scalp is cicatrical alopecia. On the ground of long lasting, untreated lesions squamous cell carcinoma (SCC) may develop. On the other hand SCC remains in the circle of DLE differentiation. We present diagnostic and therapeutic difficulties associated with DLE.

APA, Harvard, Vancouver, ISO, and other styles

28

Frances, Laura, Isabel Betlloch, Maria Leiva-Salinas, Irene Marin, and Jose Carlos Pascual. "Subacute cutaneous lupus erythematosus starting as linear lupus erythematosus." International Journal of Dermatology 55, no. 2 (July 31, 2015): 173–76. http://dx.doi.org/10.1111/ijd.12829.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Abadías-Granado, I., J. Sánchez-Bernal, F. Felipo-Berlanga, and M. Ara-Martín. "Coexistence of Tumid Lupus Erythematosus and Discoid Lupus Erythematosus." Actas Dermo-Sifiliográficas (English Edition) 110, no. 3 (April 2019): 253–55. http://dx.doi.org/10.1016/j.adengl.2019.02.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Arai, Satoru, and Kensei Katsuoka. "Clinical entity of Lupus erythematosus panniculitis/lupus erythematosus profundus." Autoimmunity Reviews 8, no. 6 (May 2009): 449–52. http://dx.doi.org/10.1016/j.autrev.2008.12.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bernardi, M., S. Bahrami, and JP Callen. "Hypertrophic lupus erythematosus complicating long-standing systemic lupus erythematosus." Lupus 20, no. 5 (February 7, 2011): 549–50. http://dx.doi.org/10.1177/0961203310385161.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Singh, Sukhraj, Sandra Sheffield, Nisha Chowdhury, Swetha Nuthulaganti, Zareen Vaghaiwalla, and Karishma Ramsubeik. "Utilization of Rituximab for Refractory Rowell Syndrome." Case Reports in Rheumatology 2021 (July 29, 2021): 1–6. http://dx.doi.org/10.1155/2021/2727382.

Full text

Abstract:

Rowell syndrome describes the occurrence of erythema multiforme-like lesions in patients with cutaneous lesions of lupus erythematosus. The clinical picture of atypical erythema multiforme-like lesions, presence of chilblains, speckled ANA pattern, anti-Ro/SSA, or anti-La/SSB antibodies, and absence of infectious or pharmacologic triggers in a patient with systemic lupus erythematosus are some of the classic clinical and serologic features. Histopathologic and serologic findings can help differentiate this process from erythema multiforme. We present a case of young woman with systemic lupus erythematosus, end-stage renal disease due to lupus nephritis, and a remote history of Steven–Johnson syndrome due to sulfa allergy who presented to the hospital with a recurrent, progressive, targetoid erythematous rash involving more than 60% of her body surface area. Our patient had several hospitalizations in the recent past for this erythematous rash and had failed oral therapy with prednisone 1 mg/kg and hydroxychloroquine. In view of the minimal improvement and increasing severity and patient exhibiting early features of mast cell activation syndrome, the patient was treated with pulse intravenous glucocorticoids followed by rituximab with an excellent response. We highlight a unique case report of progressive Rowell syndrome refractory to standard of care with an excellent response to rituximab.

APA, Harvard, Vancouver, ISO, and other styles

33

Kapoor, T. M., P. Mahadeshwar, S. Nguyen, J. Li, S. Kapoor, J. Bathon, J. Giles, and A. Askanase. "Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse." Lupus 26, no. 14 (April 11, 2017): 1473–82. http://dx.doi.org/10.1177/0961203317703494.

Full text

Abstract:

Objective In the era of powerful immunosuppression, opportunistic infections are an increasing concern in systemic lupus erythematosus. One of the best-studied opportunistic infections is Pneumocystis pneumonia; however, the prevalence of Pneumocystis pneumonia in systemic lupus erythematosus is not clearly defined. This study evaluates the prevalence of Pneumocystis pneumonia in hospitalized systemic lupus erythematosus patients, with a focus on validating the Pneumocystis pneumonia and systemic lupus erythematosus diagnoses with clinical information. Methods This retrospective cohort study evaluates the prevalence of Pneumocystis pneumonia in all systemic lupus erythematosus patients treated at Columbia University Medical Center-New York Presbyterian Hospital between January 2000 and September 2014, using electronic medical record data. Patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and patients with renal transplants (including both early and late post-transplant patients) represented immunocompromised control groups. Patients with systemic lupus erythematosus, Pneumocystis pneumonia, HIV/AIDS, or renal transplant were identified using diagnostic codes from the International Classification of Diseases, Ninth Revision (ICD-9). Results Out of 2013 hospitalized systemic lupus erythematosus patients, nine had presumed Pneumocystis pneumonia, yielding a low prevalence of Pneumocystis pneumonia in systemic lupus erythematosus of 0.45%. Three of the nine Pneumocystis pneumonia cases were patients with concomitant systemic lupus erythematosus and HIV/AIDS. Only one of these nine cases was histologically confirmed as Pneumocystis pneumonia, in a patient with concomitant systemic lupus erythematosus and HIV/AIDS and a CD4 count of 13 cells/mm3. The prevalence of Pneumocystis pneumonia in renal transplant patients and HIV/AIDS patients was 0.61% and 5.98%, respectively. Conclusion Given the reported high rate of adverse effects to trimethoprim-sulfamethoxazole in systemic lupus erythematosus and the low prevalence of Pneumocystis pneumonia in hospitalized systemic lupus erythematosus patients, our data do not substantiate the need for Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus patients, except in those with concurrent HIV/AIDS.

APA, Harvard, Vancouver, ISO, and other styles

34

Bae, E. H., S. Y. Lim, K. D. Han, J. Hy Jung, H. S. Choi, C. S. Kim, S. K. Ma, and SW Kim. "Systemic lupus erythematosus is a risk factor for cancer: a nationwide population-based study in Korea." Lupus 28, no. 3 (February 2, 2019): 317–23. http://dx.doi.org/10.1177/0961203319826672.

Full text

Abstract:

Objective Specific differences in cancer risk have been observed between systemic lupus erythematosus patients and the general population. Although meta-analyses have estimated cancer incidence in systemic lupus erythematosus patients, results have been inconclusive. Hence, we aimed to assess malignancy risk in systemic lupus erythematosus patients, compared to the risk in the general population. Methods Systemic lupus erythematosus patients ( n = 21,016; mean age 41.67 ± 13.14 years; female 90.22%) were selected from the Korean National Health Insurance Service database between 2008 and 2014. Age- and sex-matched controls were randomly sampled in a 5:1 ratio ( n = 105,080). Results During the 7 years of follow up, malignancy was detected in 763 (3.63%) systemic lupus erythematosus patients and 2667 (2.54%) controls. Systemic lupus erythematosus patients had a higher risk of malignancy than controls (odds ratio 1.44; 95% confidence interval 1.327–1.559), after multivariate adjustment. Systemic lupus erythematosus patients had a higher odds ratio for developing cervical, thyroid, ovarian, and oral cancer, as well as lymphoma, leukemia, and multiple myeloma than controls. Based on subgroup analysis, male systemic lupus erythematosus patients and patients younger than 40 years showed the highest lymphoma risk. Conclusions Systemic lupus erythematosus might be an independent risk factor for cancer. Therefore, the importance of cancer screening programs should be emphasized in systemic lupus erythematosus patients. Our study is the first large nationwide cohort study for evaluating the risk of cancer in systemic lupus erythematosus patients.

APA, Harvard, Vancouver, ISO, and other styles

35

Magro-Checa, C., L. J. J. Beaart-van de Voorde, H. A. M. Middelkoop, M. L. Dane, N. J. van der Wee, M. A. van Buchem, T. W. J. Huizinga, and G. M. Steup-Beekman. "Outcomes of neuropsychiatric events in systemic lupus erythematosus based on clinical phenotypes; prospective data from the Leiden NP SLE cohort." Lupus 26, no. 5 (April 2017): 543–51. http://dx.doi.org/10.1177/0961203316689145.

Full text

Abstract:

Objective The objective of this study was to assess whether clinical and patient’s reported outcomes are associated with a different pathophysiological origin of neuropsychiatric events presenting in systemic lupus erythematosus. Methods A total of 232 neuropsychiatric events presenting in 131 systemic lupus erythematosus patients were included. Neuropsychiatric systemic lupus erythematosus diagnosis was established per event by multidisciplinary evaluation. All neuropsychiatric events were divided according to a suspected underlying pathophysiological process into one of the following: non-neuropsychiatric systemic lupus erythematosus related, inflammatory and ischaemic neuropsychiatric systemic lupus erythematosus. The clinical outcome of all neuropsychiatric events was determined by a physician-completed four-point Likert scale. Health-related quality of life was measured with the subscales of the patient-generated Short Form 36 (SF-36) health survey questionnaire. The change between scores at paired visits of all domain scores, mental component summary (SF-36 MCS) and physical component summary (SF-36 PCS) scores were retrospectively calculated and used as patient-reported outcome. The association among these outcomes and the different origin of neuropsychiatric events was obtained using multiple logistic regression analysis. Results The clinical status of 26.8% non-neuropsychiatric systemic lupus erythematosus events, 15.8% ischaemic neuropsychiatric systemic lupus erythematosus and 51.6% inflammatory neuropsychiatric systemic lupus erythematosus improved after re-assessment. Almost all SF-36 domains had a positive change at re-assessment in all groups independently of the origin of neuropsychiatric events. Neuropsychiatric systemic lupus erythematosus ( B = 0.502; p < 0.001) and especially inflammatory neuropsychiatric systemic lupus erythematosus ( B = 0.827; p < 0.001) had better clinical outcome, with change in disease activity being the only important predictor. The change in SF-36 MCS was also independently associated with neuropsychiatric systemic lupus erythematosus ( B = 5.783; p < 0.05) and inflammatory neuropsychiatric systemic lupus erythematosus ( B = 11.133; p < 0.001). Disease duration and change in disease activity were the only predictors in both cases. The change in SF-36 PCS was only negatively associated with age. Conclusion Inflammatory neuropsychiatric systemic lupus erythematosus events have better clinical outcome and meaningful improvement in SF-36 MCS than ischaemic neuropsychiatric systemic lupus erythematosus or non-neuropsychiatric systemic lupus erythematosus.

APA, Harvard, Vancouver, ISO, and other styles

36

Abu-Shakra, M. "Safety of vaccination of patients with systemic lupus erythematosus." Lupus 18, no. 13 (October 30, 2009): 1205–8. http://dx.doi.org/10.1177/0961203309346507.

Full text

Abstract:

Live vaccines are not safe for immuno-compromised patients and should not be given to patients with systemic lupus erythematosus. In addition, all vaccines are not recommended for systemic lupus erythematosus patients when their disease is very active and mainly for patients with very active lupus nephritis. Systemic lupus erythematosus patients with quiescent or mildly active disease should be encouraged to receive vaccination according the recommendations given by the Immunization Practices Advisory Committee. Among this group of systemic lupus erythematosus patients, vaccines are safe and they do not affect the clinical manifestations of systemic lupus erythematosus including renal features, disease activity, or the requirement for steroids or cytotoxic drugs. However, vaccines may trigger the generation of autoantibodies which is usually short term and has no clinical significance. In individual cases vaccines exacerbate systemic lupus erythematosus; however, no specific clinical or laboratory variables have been identified to be associated with flare of systemic lupus erythematosus following vaccination. Lupus (2009) 18, 1205—1208.

APA, Harvard, Vancouver, ISO, and other styles

37

Bae, S. C., and Y. H. Lee. "Associations between paraoxonase-1 and systemic lupus erythematosus." Lupus 28, no. 13 (October 25, 2019): 1571–76. http://dx.doi.org/10.1177/0961203319884653.

Full text

Abstract:

Objective The objective of this analysis was to explore associations between paraoxonase-1 levels, gene polymorphisms and systemic lupus erythematosus. Methods Meta-analyses of paraoxonase-1 levels and Q192R and L55M and polymorphisms in systemic lupus erythematosus were conducted. Results Nine articles were incorporated in our meta-analysis, which uncovered that the paraoxonase-1 level was decreased in systemic lupus erythematosus compared to control (standard mean difference = −1.626, 95% confidence interval = −2.829–−0.424, p = 0.008). Ethnicity-specific meta-analysis demonstrated a relation tendency between decreased paraoxonase-1 activity and lupus in Europeans (standard mean difference = −1.236, 95% confidence interval = −2.634–0.163, p = 0.083). Paraoxonase-1 activity was reduced in systemic lupus erythematosus in a single Arab and African population. Decreased paraoxonase-1 activity was found in a small sample of systemic lupus erythematosus patients (standard mean difference = −1.642, 95% confidence interval = −3.076–−0.247, p = 0.021). Ethnicity-specific analysis indicated a relationship between the paraoxonase-1 55 M allele in the Arab systemic lupus erythematosus population. However, a lack of association with systemic lupus erythematosus and the paraoxonase-1 192 R allele was observed. Conclusions Meta-analyses revealed reduced paraoxonase-1 activity in patients with systemic lupus erythematosus and found possible associations between systemic lupus erythematosus and paraoxonase-1 L55M polymorphism in a specific ethnic group.

APA, Harvard, Vancouver, ISO, and other styles

38

Pacheco-Lugo, L., J. Sáenz-García, E. Navarro Quiroz, H. González Torres, L. Fang, Y. Díaz-Olmos, G. Garavito de Egea, E. Egea Bermejo, and G. Aroca Martínez. "Plasma cytokines as potential biomarkers of kidney damage in patients with systemic lupus erythematosus." Lupus 28, no. 1 (November 19, 2018): 34–43. http://dx.doi.org/10.1177/0961203318812679.

Full text

Abstract:

Background Systemic lupus erythematosus is a heterogeneous chronic inflammatory autoimmune disorder characterized by an exacerbated expression of cytokines and chemokines in different tissues and organs. Renal involvement is a significant contributor to the morbidity and mortality of systemic lupus erythematosus, and its diagnosis is based on renal biopsy, an invasive procedure with a high risk of complications. Therefore, the development of alternative, non-invasive diagnostic tests for kidney disease in patients with systemic lupus erythematosus is a priority. Aim To evaluate the plasma levels of a panel of cytokines and chemokines using multiplex xMAP technology in a cohort of Colombian patients with active and inactive systemic lupus erythematosus, and to evaluate their potential as biomarkers of renal involvement. Results Plasma from 40 systemic lupus erythematosus non-nephritis patients and 80 lupus nephritis patients with different levels of renal involvement were analyzed for 39 cytokines using Luminex xMAP technology. Lupus nephritis patients had significantly increased plasma eotaxin, TNF-α, interleukin-17-α, interleukin-10, and interleukin-15 as compared to the systemic lupus erythematosus non-nephritis group. Macrophage-derived chemokine, growth regulated oncogene alpha, and epidermal growth factor were significantly elevated in systemic lupus erythematosus non-nephritis patients when compared to lupus nephritis individuals. Plasma eotaxin levels allowed a discrimination between systemic lupus erythematosus non-nephritis and lupus nephritis patients, for which we performed a receiver operating characteristic curve to confirm. We observed a correlation of eotaxin levels with active nephritis (Systemic Lupus Erythematosus Disease Activity Index). Our data indicate that circulating cytokines and chemokines could be considered good predictors of renal involvement in individuals with systemic lupus erythematosus.

APA, Harvard, Vancouver, ISO, and other styles

39

Young, K. A., M. E. Munroe, J. M. Guthridge, D. L. Kamen, G. S. Gilkensen, J. B. Harley, M. H. Weisman, et al. "Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE." Lupus 28, no. 5 (March 7, 2019): 597–606. http://dx.doi.org/10.1177/0961203319834675.

Full text

Abstract:

Objective Further prospective study is needed to elucidate the etiology and natural history of systemic lupus erythematosus development. The clinical complexity of this heterogeneous disease makes study design challenging. Our objective was to ascertain useful screening factors for identifying at-risk individuals for follow-up rheumatologic assessment or inclusion in prospective studies. Methods We attempted to re-contact 3823 subjects with a family history of systemic lupus erythematosus, who did not meet American College of Rheumatology systemic lupus erythematosus classification at a baseline study visit; 436 agreed to follow-up participation an average of 6.3 years after baseline. In total, 56 of these individuals had transitioned to classified systemic lupus erythematosus (≥ 4 cumulative American College of Rheumatology criteria, verified by medical record review) by the time of follow up. Generalized estimating equations assessed associations between our dichotomous outcome of transitioning to systemic lupus erythematosus with baseline characteristics, including ANA positivity, Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score, and number of American College of Rheumatology criteria. We analyzed predictive accuracy of characteristics on transitioning. Results ANA positivity, Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score categorization of possible or probable systemic lupus erythematosus, and greater number of American College of Rheumatology criteria at baseline were each associated with transitioning to systemic lupus erythematosus classification. Being ANA positive and having confirmed immunologic criteria at baseline had the highest positive predictive value and specificity for transitioning to systemic lupus erythematosus. American College of Rheumatology Connective Tissue Disease Screening questionnaire systemic lupus erythematosus score categorization of possible or probable systemic lupus erythematosus had a better positive predictive value, negative predictive value, sensitivity, and specificity than ANA positivity. Conclusion Given limited resources, identifying individuals for follow up based on the systemic lupus erythematosus portion of the Connective Tissue Disease Screening questionnaire could be an efficient way to identify family members at highest risk of disease transition.

APA, Harvard, Vancouver, ISO, and other styles

40

Rekik, Mariem, Khadija Sellami, Massara Baklouti, Emna Bahloul, and Hamida Turki. "Oral involvement in lupus erythematosus: A report of three cases." Our Dermatology Online 13, no. 4 (October 1, 2022): 467–68. http://dx.doi.org/10.7241/ourd.20224.31.

Full text

Abstract:

Sir, Lupus erythematosus (LE) is an autoimmune disease that may rarely affect the oral mucosa. This mucosal damage may be mistaken for lichen planus. Herein, we report three cases of oral lupus. Observation 1: A 41-year-old female, with a seven-year history of systemic LE (SLE) treated with hydroxychloroquine, presented for recent food discomfort. An examination of the oral mucosa found an erythematous plaque on the palate (Fig. 1) and whitish macules on the cheek mucosa. A palatal biopsy was in favor of lupus.

APA, Harvard, Vancouver, ISO, and other styles

41

Shulman, S., R. Shorer, J. Wollman, G. Dotan, and D. Paran. "Retinal nerve fiber layer thickness and neuropsychiatric manifestations in systemic lupus erythematosus." Lupus 26, no. 13 (April 6, 2017): 1420–25. http://dx.doi.org/10.1177/0961203317703496.

Full text

Abstract:

Background Cognitive impairment is frequent in systemic lupus erythematosus. Atrophy of the corpus callosum and hippocampus have been reported in patients with systemic lupus erythematosus, and diffusion tensor imaging studies have shown impaired white matter integrity, suggesting that white matter damage in systemic lupus erythematosus may underlie the cognitive impairment as well as other neuropsychiatric systemic lupus erythematosus manifestations. Retinal nerve fiber layer thickness, as assessed by optical coherence tomography, has been suggested as a biomarker for white matter damage in neurologic disorders such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease. Retinal nerve fiber layer thinning may occur early, even in patients with mild clinical symptoms. Aim The objective of this study was to assess the association of retinal nerve fiber layer thickness, as a biomarker of white matter damage in systemic lupus erythematosus patients, with neuropsychiatric systemic lupus erythematosus manifestations, including cognitive impairment. Methods Twenty-one consecutive patients with systemic lupus erythematosus underwent neuropsychological testing using a validated computerized battery of tests as well as the Rey-Auditory verbal learning test. All 21 patients, as well as 11 healthy, age matched controls, underwent optical coherence tomography testing to assess retinal nerve fiber layer thickness. Correlations between retinal nerve fiber layer thickness and results in eight cognitive domains assessed by the computerized battery of tests as well as the Rey-Auditory verbal learning test were assessed in patients with systemic lupus erythematosus, with and without neuropsychiatric systemic lupus erythematosus, and compared to retinal nerve fiber layer thickness in healthy controls. Results No statistically significant correlation was found between retinal nerve fiber layer thickness in patients with systemic lupus erythematosus as compared to healthy controls. When evaluating by subgroups, no correlation was found between patients with or without neuropsychiatric systemic lupus erythematosus or cognitive impairment and retinal nerve fiber layer thickness. Conclusion Retinal nerve fiber layer thickness of systemic lupus erythematosus patients was not found to be statistically different compared to controls. Within systemic lupus erythematosus patients there was no correlation between retinal nerve fiber layer thickness and cognitive impairment or other neuropsychiatric systemic lupus erythematosus manifestations.

APA, Harvard, Vancouver, ISO, and other styles

42

Fabbri, Paolo, Carla Cardinali, Barbara Giomi, and Marzia Caproni. "Cutaneous Lupus Erythematosus." American Journal of Clinical Dermatology 4, no. 7 (2003): 449–65. http://dx.doi.org/10.2165/00128071-200304070-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Wu, Jianni, Juliana Berk-Krauss, and Sharon A. Glick. "Neonatal Lupus Erythematosus." JAMA Dermatology 157, no. 5 (May 1, 2021): 590. http://dx.doi.org/10.1001/jamadermatol.2021.0041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Feingold-Link, Mara. "Systemic Lupus Erythematosus." Annals of Internal Medicine 168, no. 6 (March 20, 2018): 452. http://dx.doi.org/10.7326/m17-2553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Nasef, Nehad. "Neonatal Lupus Erythematosus." Neonatology & Clinical Pediatrics 1, no. 1 (October 20, 2014): 1–10. http://dx.doi.org/10.24966/ncp-878x/100002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Bhatt, TaseerAhmed, Samara Mimesh, and HanadiA Fatani. "Congenital lupus erythematosus." Indian Journal of Dermatology 56, no. 6 (2011): 734. http://dx.doi.org/10.4103/0019-5154.91841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Kiriakidou, Marianthi. "Systemic Lupus Erythematosus." Annals of Internal Medicine 159, no. 7 (October 1, 2013): ITC4. http://dx.doi.org/10.7326/0003-4819-159-7-201310010-01004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Greenberg, Brent, and Margaret Michalska. "Systemic lupus erythematosus." Postgraduate Medicine 106, no. 6 (January 1999): 213–23. http://dx.doi.org/10.3810/pgm.1999.11.779.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Dall'Era, Maria, and John C. Davis. "Systemic lupus erythematosus." Postgraduate Medicine 114, no. 5 (November 2003): 31–40. http://dx.doi.org/10.3810/pgm.2003.11.1528.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Rao, NarayanaT, Kamal Ahmed, and K. Venkatachalam. "Lupus erythematosus profundus." Indian Journal of Dermatology, Venereology, and Leprology 76, no. 4 (2010): 448. http://dx.doi.org/10.4103/0378-6323.66612.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!